InnoCore Pharmaceuticals has signed an exclusive pharma Licensing and Collaboration Agreement with Allergan, a big pharma company.
Under the pharma licensing agreement, the companies will expand their existing collaboration and jointly continue to develop long-acting ocular drug delivery products for the treatment of ophthalmic diseases.
Utilizing its patented SynBiosys polymeric drug delivery platform, InnoCore will formulate Allergan's proprietary drugs into pharmaceutical products expected to be capable of sustained release for many months following a single ocular injection under the pharma licensing deal.
The SynBiosys drug delivery platform is based on novel biodegradable multi-block co-polymers with unique molecular architectures that allow precise and site-specific delivery of drugs for predetermined periods of time, ranging from weeks to many months.
InnoCore Pharmaceuticals is a specialty pharmaceutical company focused on the development and manufacturing of long acting injectable drug delivery products for the treatment of chronic diseases.
Utilizing its proprietary drug delivery technologies such as its unique SynBiosys polymer platform, InnoCore develops biodegradable sustained release depots for precisely controlled delivery of therapeutic compounds. Depot technologies include microspheres, solid implants, coatings and gels.
Read: more on Allergan company profile, recent partnering, M&A and financing news and articles
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity